Bookmark and Share
opioid receptor, delta 1 [Homo sapiens] [gi:119628077] - Target BioActivity Data
BioActivity Outcomes:
Active(17)
 
 
Inactive(88)
 
 
BioAssay Types:
Confirmatory(105)
 
 
 
BioActivity Types:
EC50(80)
 
 
 
IC50(25)
 
 
 
Substance Types:
Chemical(105)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 6    Data Row: 105   Total Pages: 6   Display: Page     
Sort: [Click the result table header to sort]
#StructureSubstanceCompoundActivityBioAssayLinks
OutcomeTypeValue [μM]
1
[SID144241345]
[CID10407491]
EC50 0.206Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response assay, Set 2 [AID651762, Type: confirmatory]
View
2
[SID144241350]
[CID25374006]
EC50 0.321Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response OPRD1 counterscreen, Set 2 [AID651764, Type: confirmatory]
View
3
[SID144241350]
[CID25374006]
EC50 0.394Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response assay, Set 2 [AID651762, Type: confirmatory]
View
4
[SID134220670]
[CID23723457]
EC50 0.403Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response assay [AID651685, Type: confirmatory]
View
5
[SID144241343]
[CID16189614]
EC50 0.605Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response assay, Set 2 [AID651762, Type: confirmatory]
View
6
[SID24798818]
[CID16190489]
EC50 0.901Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response assay [AID651685, Type: confirmatory]
View
7
[SID134220670]
[CID23723457]
EC50 1.1Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response OPRD1 counterscreen [AID651686, Type: confirmatory]
View
8
[SID144087321]
[CID60156232]
IC50 2.5Late-stage results from the probe development effort to identify antagonists of OPRK1: fluorescence-based cell-based dose response OPRD1 counterscreen [AID652033, Type: confirmatory]
View
9
[SID144087322]
[CID60156234]
IC50 3Late-stage results from the probe development effort to identify antagonists of OPRK1: fluorescence-based cell-based dose response OPRD1 counterscreen [AID652033, Type: confirmatory]
View
10
[SID144087298]
[CID60156210]
IC50 3.36Late-stage results from the probe development effort to identify antagonists of OPRK1: fluorescence-based cell-based dose response OPRD1 counterscreen [AID652033, Type: confirmatory]
View
11
[SID144087319]
[CID60156214]
IC50 3.5Late-stage results from the probe development effort to identify antagonists of OPRK1: fluorescence-based cell-based dose response OPRD1 counterscreen [AID652033, Type: confirmatory]
View
12
[SID160844000]
[CID2812682]
IC50 4.38Late-stage results from the probe development effort to identify antagonists of OPRK1: fluorescence-based cell-based dose response OPRD1 counterscreen, Set 2 [AID652080, Type: confirmatory]
View
13
[SID24783721]
[CID16188233]
EC50 4.4Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response assay [AID651685, Type: confirmatory]
View
14
[SID144241359]
[CID45227873]
EC50 5.16Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response assay, Set 2 [AID651762, Type: confirmatory]
View
15
[SID131465556]
[CID54669714]
EC50 7Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response assay [AID651685, Type: confirmatory]
View
16
[SID144087314]
[CID60156217]
IC50 7Late-stage results from the probe development effort to identify antagonists of OPRK1: fluorescence-based cell-based dose response OPRD1 counterscreen [AID652033, Type: confirmatory]
View
17
[SID131269005]
[CID16187284]
EC50 8.9Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response assay [AID651685, Type: confirmatory]
View
18
[SID47199793]
[CID23723958]
EC50 10.3Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response assay [AID651685, Type: confirmatory]
View
19
[SID144087313]
[CID60156237]
IC50 12Late-stage results from the probe development effort to identify antagonists of OPRK1: fluorescence-based cell-based dose response OPRD1 counterscreen [AID652033, Type: confirmatory]
View
20
[SID144087310]
[CID60156240]
IC50 18Late-stage results from the probe development effort to identify antagonists of OPRK1: fluorescence-based cell-based dose response OPRD1 counterscreen [AID652033, Type: confirmatory]
View